Rapport Therapeutics Inc
RAPPHealthcare|Biotechnology|USA
$41.79
-0.25 (-0.60%)
Tangible Book
$9.86
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07594119 Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures | Focal Seizure, Epilepsy | P3 | Recruiting | 312 | RCT, Double-blind | RAP-219, RAP-219 |
| NCT07563881 Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 | Focal Seizure, Epilepsy | P3 | Recruiting | 333 | RCT, Double-blind | RAP-219, RAP-219 |
| NCT07046494 Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder | Bipolar 1 Disorder | P2 | Recruiting | 250 | RCT, Double-blind | RAP-219 |
| NCT07219407 A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures | Focal Epilepsy, Epilepsy | P2 | Recruiting | 30 | Open-label | RAP-219 |
| NCT06377930 Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy | Focal Onset Seizures | P2 | Completed | 30 | Open-label | RAP-219 |